The dataset behind this landscape contains 5,128 published records filed or published between 2015 and mid-2026 that combine stem or progenitor cell culture language with a specific formulation lever such as amino acids, growth factors, lipid supplements or serum replacement, within the core IPC classes for animal cell culture technique and culture apparatus. This is a scoped count based on the search string used, not a count of every patent that could conceivably touch stem cell media. Broader or narrower search terms will produce a different total, so treat this figure as representative of the defined scope rather than an absolute field size.

One assignee leads clearly with 408 records, well ahead of the fifth-ranked filer at 128 and the tenth at 98. The top five assignees combined hold 24.8% of all 5,128 records in scope, and the top ten hold 35.3%. Beyond that concentrated top tier, the ranked leaders — 100 companies in total from this dataset’s ranking — thin out into a long tail of academic institutions, cell-therapy developers and single-filing entrants, which is typically where the most open claim space sits.

Filing volume peaked in 2018 at 323 records and has declined since; the last three-year span that can be read as complete, 2021 to 2024, shows filings falling from 203 to 82, a 60% drop. Because publication typically lags filing by roughly 18 months, the 2025 and 2026 counts in any chart of this data will look artificially low and should not be read as continued decline until later publications catch up. On the evidence available through 2024, though, the trend is a genuine pullback from the 2018 peak rather than a plateau.